

# Contents



<b>Financial highlights</b>	<b>2</b>
■ Consolidated financial summary	2
■ Consolidated balance sheets summary	2
■ Consolidated financial indexes	2
■ Consolidated other figures	2
<b>Consolidated information</b>	<b>4</b>
Consolidated income statements	4
Income statements details	5
■ Major Selling, general and administrative expenses	5
■ Major Non-operating income and expenses	5
■ Major Extraordinary gain and loss	5
Sales details	6
■ Sales of major prescription pharmaceuticals	6
■ Sales by division	8
Breakdown by geographic segment	9
■ Breakdown by geographic segment	9
■ Overseas sales	9
Consolidated balance sheets	10
■ Assets	10
■ Liabilities and net assets	11
Consolidated statements of cash flows	12
Capital expenditures and number of employees	13
■ Capital expenditures	13
■ Depreciation and amortization	13
■ Lease expenses	13
■ Number of employees	13
<b>Reference information</b>	<b>14</b>
Research & development	14
■ Pipeline of prescription pharmaceuticals (Clinical studies)	14
■ License out	15
■ Changes from August 4, 2009	15
Pharmaceutical market in Japan	16
■ Revision of National Health Insurance (NHI) drug prices	16
■ Major healthcare reforms and related information	16
■ Market shares	17
■ Market shares by therapeutic area - prescription ophthalmics	17
Stock information	18
■ Stock price	18
■ Major shareholders	18
■ Stock option	18
■ Purchase of Treasury stock	18
■ Breakdown of shareholding by number of shares	19
■ Breakdown of shareholding by number of shareholders	19
Consolidated subsidiaries	20
News releases	21